Functional differences and interactions between the escherichia coli type III secretion system effectors NleH1 and NleH2

Infection and Immunity

Volumn 80, Issue 6, 2012, Pages 2133-2140

  Pham, Thanh H ^a   Gao, Xiaofei ^a   Tsai, Karen ^a   Olsen, Rachel ^a   Wan, Fengyi ^b   Hardwidge, Philip R ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NLEH1 PROTEIN; NLEH2 PROTEIN; UNCLASSIFIED DRUG; ESCHERICHIA COLI PROTEIN; NLEH PROTEIN, E COLI; RIBOSOMAL PROTEIN S3; RIBOSOME PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL CELL; BACTERIAL COLONIZATION; BACTERIAL TRANSLOCATION; BACTERIAL VIRULENCE; CITROBACTER; CONTROLLED STUDY; ENZYME ACTIVATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; HOST CELL; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TYPE III SECRETION SYSTEM; ANIMAL; C3H MOUSE; C57BL MOUSE; CELL STRAIN HEK293; CITROBACTER RODENTIUM; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI O157; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; HUMAN; METABOLISM; MICROBIOLOGY; MUTATION; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CITROBACTER RODENTIUM; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI O157; ESCHERICHIA COLI PROTEINS; GENE EXPRESSION REGULATION, BACTERIAL; HEK293 CELLS; HELA CELLS; HUMANS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MUTATION; NF-KAPPA B; PROTEIN BINDING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS;

EID: 85047686900     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06358-11     Document Type: Article

References (27)

1. Baruch K, et al. 2011. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. EMBO J. 30:221-231.
2. Coombes BK, et al. 2008. Molecular analysis as an aid to assess the public health risk of non-O157 Shiga toxin-producing Escherichia coli strains. Appl. Environ. Microbiol. 74:2153-2160.
3. Cornelis GR. 2010. The type III secretion injectisome, a complex nanomachine for intracellular 'toxin' delivery. Biol. Chem. 391:745-751.
4. Deng W, Li Y, Vallance BA, Finlay BB. 2001. Locus of enterocyte effacement from Citrobacter rodentium: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect. Immun. 69:6323- 6335.
5. Deng W, et al. 2004. Dissecting virulence: systematic and functional analyses of a pathogenicity island. Proc. Natl. Acad. Sci. U. S. A. 101:3597- 3602.
6. Gao X, et al. 2009. Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog. 5:e1000708.
7. Garcia-Angulo VA, Deng W, Thomas NA, Finlay BB, Puente JL. 2008. Regulation of expression and secretion of NleH, a new non-locus of enterocyte effacement-encoded effector in Citrobacter rodentium. J. Bacteriol. 190:2388 -2399.
8. Hemrajani C, et al. 2010. NleH effectors interact with Bax inhibitor-1 to block apoptosis during enteropathogenic Escherichia coli infection. Proc. Natl. Acad. Sci. U. S. A. 107:3129 -3134.
9. Hemrajani C, et al. 2008. Role of NleH, a type III secreted effector from attaching and effacing pathogens, in colonization of the bovine, ovine, and murine gut. Infect. Immun. 76:4804-4813.
10. Kim DW, et al. 2005. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc. Natl. Acad. Sci. U. S. A. 102:14046 -14051.
11. Levine MM, et al. 1978. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are noninvasive. Lancet i:1119 -1122.
12. Martinez E, et al. 2010. Binding to Na(+)/H(+) exchanger regulatory factor 2 (NHERF2) affects trafficking and function of the enteropathogenic Escherichia coli type III secretion system effectors Map, EspI and NleH1. Cell. Microbiol. 12:1718 -1731.
13. McDaniel TK, Jarvis KG, Donnenberg MS, Kaper JB. 1995. A genetic locus of enterocyte effacement conserved among diverse enterobacterial pathogens. Proc. Natl. Acad. Sci. U. S. A. 92:1664 -1668.
14. Mead PS, et al. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607- 625.
15. Muhlen S, Ruchaud-Sparagano MH, Kenny B. 2011. Proteasomeindependent degradation of canonical NFkappaB complex components by the NleC protein of pathogenic Escherichia coli. J. Biol. Chem. 286: 5100-5107.
16. Nadler C, et al. 2010. The type III secretion effector NleE inhibits NFkappaB activation. PLoS Pathog. 6:e1000743.
17. Newton HJ, et al. 2010. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog. 6:e1000898.
18. Pearson JS, Riedmaier P, Marches O, Frankel G, Hartland EL. 2011. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol. Microbiol. 80:219 -230.
19. Petty NK, et al. 2010. The Citrobacter rodentium genome sequence reveals convergent evolution with human pathogenic Escherichia coli. J. Bacteriol. 192:525-538.
20. Robinson KS, et al. 2010. The enteropathogenic Escherichia coli effector NleH inhibits apoptosis induced by Clostridium difficile toxin B. Microbiology 156:1815-1823.
21. Royan SV, et al. 2010. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation. Mol. Microbiol. 78:1232-1245.
22. Ruchaud-Sparagano MH, Muhlen S, Dean P, Kenny B. 2011. The enteropathogenic E. coli (EPEC) Tir effector inhibits NF-kappaB activity by targeting TNFalpha receptor-associated factors. PLoS Pathog. 7:e1002414.
23. Schauer DB, Falkow S. 1993. Attaching and effacing locus of a Citrobacter freundii biotype that causes transmissible murine colonic hyperplasia. Infect. Immun. 61:2486 -2492.
24. Shames SR, et al. 2011. The pathogenic Escherichia coli type III secreted protease NleC degrades the host acetyltransferase p300. Cell. Microbiol. 13:1542-1557.
25. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926 -941.
26. Wan F, et al. 2007. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell 131: 927-939.
27. Wan F, et al. 2011. IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function during infection with Escherichia coli strain O157:H7. Nat. Immunol. 12:335-343.